论文部分内容阅读
目的:观察甲基强的松龙联合乳糖酸红霉素治疗小儿支原体肺炎的临床疗效。方法:选取2015年1月至2016年10月我院收治的90例支原体肺炎患儿,按照随机数字表法随机分为研究组和对照组,每组45例,研究组给予甲基强的松龙联合乳糖酸红霉素进行治疗,对照组给予乳糖酸红霉素进行治疗,治疗一周后对比两组患儿的治疗效果以及不良反应发生情况。结果:研究组患儿45例,治愈25例(55.56%),显效10例(22.22%),有效8例(17.78%),无效1例(4.44%),临床总有效率为95.56%,明显高于对照组,差异具有统计学意义(P<0.05)。两组患者治疗后部分病例出现不良反应现象,对照组不良反应发生率为8.88%,研究组不良反应发生率为10.00%,两组患儿不良反应发生率比较相差无几(P>0.05)。结论:甲基强的松龙联合乳糖酸红霉素治疗小儿支原体肺炎临床疗效显著,安全性高,值得临床推广使用。
Objective: To observe the clinical efficacy of methylprednisolone combined with erythromycin lactobion in children with mycoplasma pneumonia. Methods: Ninety children with mycoplasma pneumonia admitted in our hospital from January 2015 to October 2016 were randomly divided into study group and control group according to the random number table method, with 45 cases in each group. The study group was given methylprednisolone Long combined erythromycin lactobionate treatment, the control group was given erythromycin lactobionate treatment, after a week of treatment compared two groups of children with treatment and adverse reactions. Results: In the study group, 45 cases were cured, 25 cases were cured (55.56%), 10 cases (22.22%) were effective, 8 cases (17.78%) effective and 1 case (4.44%) ineffective. The total effective rate was 95.56% Higher than the control group, the difference was statistically significant (P <0.05). Adverse reactions occurred in some cases after treatment in both groups. The incidence of adverse reactions in the control group was 8.88% and the incidence of adverse reactions in the study group was 10.00%. The incidence of adverse reactions in both groups was almost the same (P> 0.05). Conclusion: Methylprednisolone combined with erythromycin lactobionate has a significant clinical effect in treating children with mycoplasma pneumonia. It is safe and worthy of clinical application.